02161.HK
JBM (Healthcare) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 1.89
+1.61%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 834.6M | 782.3M | 648.4M | 520.3M |
| Cost of Revenue | 737.7M | 369.1M | 368.6M | 310.3M | 332.4M |
| Gross Profit | 879.2M | 465.5M | 413.7M | 338.1M | 187.9M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 397.6M | 211.8M | 185.7M | 180.2M | 137.7M |
| General & Admin Expense | 105.5M | — | 63.3M | 41.7M | 53.8M |
| Selling & Marketing Expense | 191.8M | — | 122.5M | 138.5M | 84.0M |
| Other Expenses | (18.1M) | — | (18.1M) | (16.3M) | 2.7M |
| Total Operating Expenses | 379.5M | 211.8M | 167.6M | 163.9M | 120.1M |
| Cost and Expenses | 1.1B | 580.9M | 536.2M | 474.2M | 452.6M |
| Operating Income (EBIT) | 499.8M | 253.7M | 246.1M | 174.2M | 67.8M |
| Non-Operating | |||||
| Interest Income | 2.4M | 800.0K | 1.6M | 762.0K | 272.0K |
| Interest Expense | 16.1M | 11.7M | 4.5M | 8.5M | 8.2M |
| Net Interest Income | (13.8M) | (10.9M) | (2.9M) | (7.7M) | (7.9M) |
| Other Non-Op Income/Expense | (5.9M) | (1.5M) | (4.4M) | (9.3M) | (10.1M) |
| Non-Operating Income (excl Interest) | 3.8M | — | (66.0K) | 817.0K | 1.9M |
| EBT (Pre-Tax Income) | 493.8M | 252.2M | 241.7M | 164.9M | 78.8M |
| Income Tax Expense | 80.8M | 41.8M | 39.0M | 27.7M | 13.6M |
| Bottom Line | |||||
| Net Income | 398.3M | 201.1M | 197.3M | 130.5M | 57.1M |
| Earnings from Cont. Ops | 413.0M | 210.3M | 202.7M | 137.2M | 63.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 398.3M | 201.1M | 197.3M | 130.5M | 57.1M |
| Per Share | |||||
| Basic EPS | HK$0.49 | HK$0.25 | HK$0.24 | HK$0.15 | HK$0.06 |
| Diluted EPS | HK$0.49 | HK$0.25 | HK$0.24 | HK$0.15 | HK$0.06 |
| Revenue Per Share | HK$1.97 | HK$1.02 | HK$0.95 | HK$0.73 | HK$0.58 |
| Shares | |||||
| Basic Shares Outstanding | 819.0M | 816.6M | 819.2M | 883.7M | 891.3M |
| Diluted Shares Outstanding | 819.0M | 816.6M | 819.2M | 883.7M | 891.4M |
| Profitability Metrics | |||||
| EBITDA | 581.1M | 303.4M | 298.4M | 220.7M | 111.4M |
| D&A | 85.2M | 49.7M | 52.3M | 46.5M | 43.6M |
| EBIT | 496.0M | 253.7M | 246.1M | 173.4M | 85.1M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026